CCAAT/Enhancer-Binding Protein-α Suppresses Lung Tumor Development in Mice through the p38α MAP Kinase Pathway

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Sato, Atsuyasu ^a   Yamada, Norishige ^a   Ogawa, Yuya ^a   Ikegami, Machiko ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; MITOGEN ACTIVATED PROTEIN KINASE 14; URETHAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE DELETION; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG ADENOMA; LUNG TUMOR; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL TIME; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL DEATH; CELL PROLIFERATION; CHEMICALLY INDUCED; DISEASE COURSE; DISEASE MODEL; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HOMOZYGOTE; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PROMOTER REGION; SIGNAL TRANSDUCTION;

ANIMALS; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DEATH; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HOMOZYGOTE; LUNG NEOPLASMS; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROMOTER REGIONS, GENETIC; SIGNAL TRANSDUCTION; URETHANE;

EID: 84874261272     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057013     Document Type: Article

References (50)

1. Biesalski HK, Bueno de Mesquita B, Chesson A, Chytil F, Grimble R, et al. (1998) European Consensus Statement on Lung Cancer: risk factors and prevention. Lung Cancer Panel CA: a cancer journal for clinicians 48: 167-176 discussion 164-166.
2. Fong KM, Sekido Y, Gazdar AF, Minna JD, (2003) Lung cancer. 9: Molecular biology of lung cancer: clinical implications. Thorax 58: 892-900.
3. Schuster MB, Porse BT, (2006) C/EBPalpha: a tumour suppressor in multiple tissues? Biochim Biophys Acta 1766: 88-103.
4. Lopez RG, Garcia-Silva S, Moore SJ, Bereshchenko O, Martinez-Cruz AB, et al. (2009) C/EBPalpha and beta couple interfollicular keratinocyte proliferation arrest to commitment and terminal differentiation. Nat Cell Biol 11: 1181-1190.
5. Ramji DP, Foka P, (2002) CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem J 365: 561-575.
6. Nord M, Cassel TN, Braun H, Suske G, (2000) Regulation of the Clara cell secretory protein/uteroglobin promoter in lung. Ann N Y Acad Sci 923: 154-165.
7. Martis PC, Whitsett JA, Xu Y, Perl AK, Wan H, et al. (2006) C/EBP{alpha} is required for lung maturation at birth. Development 133: 1155-1164.
8. Xu Y, Saegusa C, Schehr A, Grant S, Whitsett JA, et al. (2009) C/EBP{alpha} is required for pulmonary cytoprotection during hyperoxia. Am J Physiol Lung Cell Mol Physiol 297: L286-298.
9. Sato A, Xu Y, Whitsett JA, Ikegami M, (2012) C/EBPalpha Regulates the Protease/Anti-protease Balance Required for Bronchiolar Epithelium Regeneration. Am J Respir Cell Mol Biol.
10. Costa DB, Li S, Kocher O, Feins RH, Keller SM, et al. (2007) Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer 56: 97-103.
11. Halmos B, Huettner CS, Kocher O, Ferenczi K, Karp DD, et al. (2002) Down-regulation and antiproliferative role of C/EBPalpha in lung cancer. Cancer Res 62: 528-534.
12. Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, et al. (2006) Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer. J Natl Cancer Inst 98: 396-406.
13. Timchenko NA, Harris TE, Wilde M, Bilyeu TA, Burgess-Beusse BL, et al. (1997) CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. Mol Cell Biol 17: 7353-7361.
14. Costa DB, Dayaram T, D'Alo F, Wouters BJ, Tenen DG, et al. (2006) C/EBP alpha mutations in lung cancer. Lung Cancer 53: 253-254.
15. Grandinetti KB, Stevens TA, Ha S, Salamone RJ, Walker JR, et al. (2011) Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPalpha. Oncogene 30: 3328-3335.
16. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, et al. (2007) p38alpha MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39: 750-758.
17. Stathopoulos GT, Sherrill TP, Cheng DS, Scoggins RM, Han W, et al. (2007) Epithelial NF-kappaB activation promotes urethane-induced lung carcinogenesis. Proc Natl Acad Sci U S A 104: 18514-18519.
18. Nikitin AY, Alcaraz A, Anver MR, Bronson RT, Cardiff RD, et al. (2004) Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res 64: 2307-2316.
19. Mahler JF, Stokes W, Mann PC, Takaoka M, Maronpot RR, (1996) Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 24: 710-716.
20. Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D, (2008) Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 68: 3689-3696.
21. Ushijima T, Okochi-Takada E, (2005) Aberrant methylations in cancer cells: where do they come from? Cancer Sci 96: 206-211.
22. Ushijima T, (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5: 223-231.
23. Oeztuerk-Winder F, Guinot A, Ochalek A, Ventura JJ, (2012) Regulation of human lung alveolar multipotent cells by a novel p38alpha MAPK/miR-17-92 axis. EMBO J 31: 3431-3441.
24. Forkert PG, (2010) Mechanisms of lung tumorigenesis by ethyl carbamate and vinyl carbamate. Drug Metab Rev 42: 355-378.
25. Sato A, Xu Y, Whitsett JA, Ikegami M, (2012) CCAAT/Enhancer Binding Protein-alpha Regulates the Protease/Antiprotease Balance Required for Bronchiolar Epithelium Regeneration. Am J Respir Cell Mol Biol 47: 454-463.
26. Magert HJ, Standker L, Kreutzmann P, Zucht HD, Reinecke M, et al. (1999) LEKTI, a novel 15-domain type of human serine proteinase inhibitor. J Biol Chem 274: 21499-21502.
27. Oikonomopoulou K, Diamandis EP, Hollenberg MD, (2010) Kallikrein-related peptidases: proteolysis and signaling in cancer, the new frontier. Biol Chem 391: 299-310.
28. Cisowski J, O'Callaghan K, Kuliopulos A, Yang J, Nguyen N, et al. (2011) Targeting protease-activated receptor-1 with cell-penetrating pepducins in lung cancer. Am J Pathol 179: 513-523.
29. Shim M, Powers KL, Ewing SJ, Zhu S, Smart RC, (2005) Diminished expression of C/EBPalpha in skin carcinomas is linked to oncogenic Ras and reexpression of C/EBPalpha in carcinoma cells inhibits proliferation. Cancer Res 65: 861-867.
30. Jin J, Wang GL, Timchenko L, Timchenko NA, (2009) GSK3beta and aging liver. Aging 1: 582-585.
31. Timchenko NA, (2009) Aging and liver regeneration. Trends in endocrinology and metabolism: TEM 20: 171-176.
32. Loomis KD, Zhu S, Yoon K, Johnson PF, Smart RC, (2007) Genetic ablation of CCAAT/enhancer binding protein alpha in epidermis reveals its role in suppression of epithelial tumorigenesis. Cancer Res 67: 6768-6776.
33. Slomiany BA, D'Arigo KL, Kelly MM, Kurtz DT, (2000) C/EBPalpha inhibits cell growth via direct repression of E2F-DP-mediated transcription. Mol Cell Biol 20: 5986-5997.
34. Wang H, Iakova P, Wilde M, Welm A, Goode T, et al. (2001) C/EBPalpha arrests cell proliferation through direct inhibition of Cdk2 and Cdk4. Mol Cell 8: 817-828.
35. Muller C, Calkhoven CF, Sha X, Leutz A, (2004) The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest. The Journal of biological chemistry 279: 7353-7358.
36. Timchenko NA, Wilde M, Darlington GJ, (1999) C/EBPalpha regulates formation of S-phase-specific E2F-p107 complexes in livers of newborn mice. Molecular and cellular biology 19: 2936-2945.
37. Dhawan P, Wieder R, Christakos S, (2009) CCAAT enhancer-binding protein alpha is a molecular target of 1,25-dihydroxyvitamin D3 in MCF-7 breast cancer cells. The Journal of biological chemistry 284: 3086-3095.
38. Muller C, Calkhoven CF, Sha X, Leutz A, (2004) The CCAAT enhancer-binding protein alpha (C/EBPalpha) requires a SWI/SNF complex for proliferation arrest. J Biol Chem 279: 7353-7358.
39. Iakova P, Awad SS, Timchenko NA, (2003) Aging reduces proliferative capacities of liver by switching pathways of C/EBPalpha growth arrest. Cell 113: 495-506.
40. Wang GL, Timchenko NA, (2005) Dephosphorylated C/EBPalpha accelerates cell proliferation through sequestering retinoblastoma protein. Mol Cell Biol 25: 1325-1338.
41. Wang GL, Salisbury E, Shi X, Timchenko L, Medrano EE, et al. (2008) HDAC1 cooperates with C/EBPalpha in the inhibition of liver proliferation in old mice. J Biol Chem 283: 26169-26178.
42. Khanna-Gupta A, (2008) Sumoylation and the function of CCAAT enhancer binding protein alpha (C/EBP alpha). Blood Cells Mol Dis 41: 77-81.
43. Efimova T, Deucher A, Kuroki T, Ohba M, Eckert RL, (2002) Novel protein kinase C isoforms regulate human keratinocyte differentiation by activating a p38 delta mitogen-activated protein kinase cascade that targets CCAAT/enhancer-binding protein alpha. J Biol Chem 277: 31753-31760.
44. Geest CR, Buitenhuis M, Laarhoven AG, Bierings MB, Bruin MC, et al. (2009) p38 MAP kinase inhibits neutrophil development through phosphorylation of C/EBPalpha on serine 21. Stem Cells 27: 2271-2282.
45. Qiao L, MacDougald OA, Shao J, (2006) CCAAT/enhancer-binding protein alpha mediates induction of hepatic phosphoenolpyruvate carboxykinase by p38 mitogen-activated protein kinase. J Biol Chem 281: 24390-24397.
46. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, et al. (2007) p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39: 741-749.
47. Cheriyan J, Webb AJ, Sarov-Blat L, Elkhawad M, Wallace SM, et al. (2011) Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 123: 515-523.
48. Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, et al. (2012) An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 52: 416-424.
49. Basseres DS, D'Alo F, Yeap BY, Lowenberg EC, Gonzalez DA, et al. (2012) Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer 77: 31-37.
50. Halmos B, Basseres DS, Monti S, D'Alo F, Dayaram T, et al. (2004) A transcriptional profiling study of CCAAT/enhancer binding protein targets identifies hepatocyte nuclear factor 3 beta as a novel tumor suppressor in lung cancer. Cancer Res 64: 4137-4147.